Lipid Management with Bempedoic Acid
Introduction to Bempedoic Acid Therapy
- Bempedoic acid is recommended by the American College of Cardiology as an effective adjunct therapy for patients with hypercholesterolemia who require additional LDL-C lowering beyond maximally tolerated statin therapy, particularly valuable for statin-intolerant patients due to its liver-selective activation that avoids muscle-related side effects 1
- The American Heart Association and the American College of Cardiology suggest that bempedoic acid is indicated as an adjunct to diet and maximally tolerated statin therapy for adults with heterozygous familial hypercholesterolemia or established ASCVD requiring additional LDL-C lowering, based on strong evidence 2
Patient Selection for Bempedoic Acid Therapy
- Adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional LDL-C lowering may be considered for bempedoic acid therapy, as recommended by the American College of Cardiology 1
- Patients with statin intolerance due to muscle-related side effects may benefit from bempedoic acid therapy, according to the National Lipid Association, based on moderate-quality evidence 2
- The American College of Cardiology suggests considering bempedoic acid for patients with established ASCVD who have not achieved ≥50% LDL-C reduction and LDL-C <70 mg/dL on maximally tolerated statin therapy 1
Efficacy of Bempedoic Acid
- Bempedoic acid reduces LDL-C by approximately 24.5% in statin-intolerant patients when used as monotherapy, and up to 38% when combined with ezetimibe, as reported by the American College of Cardiology 1
- Bempedoic acid significantly lowers non-HDL cholesterol, total cholesterol, and apolipoprotein B, as noted by the European Atherosclerosis Society 2
- Bempedoic acid reduces high-sensitivity C-reactive protein (hs-CRP) by approximately 24.3%, indicating its anti-inflammatory effects, as reported by the American Heart Association 2
- The CLEAR Outcomes trial demonstrated that bempedoic acid reduced the composite outcome of four-point major adverse cardiovascular events by 13% compared with placebo, as reported by the American Diabetes Association, based on high-quality evidence 2, 3
Safety and Monitoring of Bempedoic Acid
- Bempedoic acid is associated with an increased risk of gout (1.2-1.5% vs. 0.3-0.4% with placebo) due to elevated uric acid levels, and patients on bempedoic acid therapy should be monitored for elevated uric acid levels and symptoms of gout, as recommended by the European Medicines Agency and the American College of Cardiology, based on low-quality evidence 2, 1
- Bempedoic acid is also associated with slight increases in tendon rupture, benign prostatic hyperplasia, atrial fibrillation, and elevated creatine kinase levels 1
- Monitoring for potential side effects including elevated uric acid levels and tendon disorders is recommended by the European Medicines Agency and the American College of Cardiology, based on low-quality evidence 2, 1
Mechanism of Action and Pharmacology
- Bempedoic acid works by inhibiting ATP-citrate lyase (ACL), an enzyme upstream of HMG-CoA reductase in the cholesterol biosynthesis pathway, resulting in decreased hepatic cholesterol synthesis and upregulation of LDL receptors that improve LDL clearance from the bloodstream, according to the American College of Cardiology 1
- The inhibition of ATP-citrate lyase reduces acetyl-CoA availability for cholesterol synthesis, as reported by the American Heart Association 4
- Bempedoic acid has a liver-selective action due to the activating enzyme ACSVL1 being expressed primarily in the liver, which provides a potential advantage for patients with statin-associated muscle symptoms, as stated by the American College of Cardiology 1
Cost and Accessibility of Bempedoic Acid
- The American College of Cardiology considers the cost implications of bempedoic acid therapy, as it is available as a branded product, and has a higher cost than generic statins and ezetimibe 1
- Patient assistance programs and discount copay cards are available for eligible patients, as noted by the American College of Cardiology 1
- Bempedoic acid may be considered after ezetimibe or PCSK9 inhibitors in the treatment algorithm, according to the American College of Cardiology 1
- Bempedoic acid is available as monotherapy or in fixed-dose combination with ezetimibe, as noted by the American College of Cardiology 1